Dunican Kaelen C, DelDotto Dana
School of Pharmacy-Worcester, Massachusetts College of Pharmacy and Health Sciences, Worcester, MA 01608, USA.
Ann Pharmacother. 2007 Jan;41(1):111-5. doi: 10.1345/aph.1H297. Epub 2006 Dec 26.
To evaluate the role of olanzapine in the treatment of anorexia nervosa.
Literature was obtained through searches of MEDLINE (1966-December 2006), EMBASE (1980-4th Quarter 2006), and PsycINFO (1985-December 2006) and a bibliographic review of published articles. Key terms used in the searches included anorexia nervosa, antipsychotics, eating disorders, olanzapine, and Zyprexa.
All English language articles that were identified from the search were evaluated. All primary literature was included in the review.
In several case reports and most clinical trials, patients with anorexia nervosa successfully gained weight while being treated with olanzapine. Moreover, many patients treated with olanzapine achieved a healthy body weight. Case reports and trials identified additional benefits of olanzapine, including reduction in delusional thinking; improvement in body image, sleep, depressive symptoms, adherence to treatment, and eating-disorder symptoms; and decreased agitation and premeal anxiety.
Preliminary evidence supports the use of olanzapine for treatment of anorexia nervosa by demonstrating that olanzapine 2.5-15 mg daily promotes weight gain and has positive effects on associated psychological symptoms. Limitations of the reported data include small sample size, low completion rate in clinical trials, and open-label trial design. Although olanzapine appears to have a potential role in the treatment of anorexia nervosa that has been unresponsive to other therapy, randomized, placebo-controlled studies with larger sample sizes are necessary to establish its role in therapy.
评估奥氮平在神经性厌食症治疗中的作用。
通过检索MEDLINE(1966年至2006年12月)、EMBASE(1980年至2006年第4季度)和PsycINFO(1985年至2006年12月)以及对已发表文章进行文献综述获取文献。检索中使用的关键词包括神经性厌食症、抗精神病药物、饮食失调、奥氮平和再普乐。
对检索到的所有英文文章进行评估。所有原始文献均纳入综述。
在几例病例报告和大多数临床试验中,神经性厌食症患者在接受奥氮平治疗时成功增重。此外,许多接受奥氮平治疗的患者达到了健康体重。病例报告和试验确定了奥氮平的其他益处,包括减少妄想思维;改善身体形象、睡眠、抑郁症状、治疗依从性和饮食失调症状;以及减少激动和餐前焦虑。
初步证据支持使用奥氮平治疗神经性厌食症,表明每日2.5 - 15毫克奥氮平可促进体重增加,并对相关心理症状有积极影响。报告数据的局限性包括样本量小、临床试验完成率低以及开放标签试验设计。尽管奥氮平似乎在治疗对其他疗法无反应的神经性厌食症方面有潜在作用,但需要进行更大样本量的随机、安慰剂对照研究来确定其在治疗中的作用。